CoChat

Haematologic responses to primaquine used for radical cure of Plasmodium vivax in public health facilities in Ethiopia: a prospective observational study

Open access

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index; none of the 37 sources its claims cite is checked for support yet.

Abstract

BACKGROUND: Malaria, caused by Plasmodium falciparum and Plasmodium vivax, is commonly reported in Ethiopia. The World Health Organization (WHO) recommends treating P. vivax malaria with a schizonticidal drug and a 14-day course of primaquine (0.25-0.5 mg/kg body weight daily) to prevent relapses. In 2018, Ethiopia adopted a policy of primaquine radical cure (0.25 mg/kg for 14 days), with close monitoring for adverse events, but without prior glucose-6-phosphate dehydrogenase (G6PD) testing. This study aimed to assess the safety of this policy by monitoring the risk of haemolysis and other adverse events following the administration of primaquine. METHODS: A prospective observational study was conducted from May 2019 to June 30, 2021, enrolling patients with P. vivax and mixed malaria at four health centres. The clinics were chosen based on their P. vivax malaria patient volume and the expected prevalence of G6PD deficiency. Clinical, laboratory, and treatment data were gathered from patients at baseline and again on days 3, 7, 13, and 27. On day 13, all patients were evaluated for G6PD deficiency using the CareStart qualitative or SD Biosensor quantitative tests. RESULTS: A total of 879 patients were enrolled; none had G6PD deficiency. Among the 298 female patients tested with the SD Biosensor, 3 (1.0%) were found to have intermediate deficiency. On day three, the median fractional fall in haemoglobin was - 0.9% (range - 51.9-61.3). Nine patients had a drop in haemoglobin of more than 25% from baseline, of whom two patients had a haemoglobin level below 8 g/dL. On day 7, the median fractional drop was 0.8% (range - 51.9-48.3%). Five patients had a > 25% decline in haemoglobin between day three to day 7. None of the patients with the haemoglobin drop exhibited clinical symptoms attributable to haemolytic anaemia. By day 13, 91.9% of the patients had haematological recovery. No serious adverse events were reported. CONCLUSIONS: In this study, conducted in a population with a low prevalence of G6PD deficiency, a 14-day regimen of low-dose primaquine was well tolerated and resulted in few mild adverse events only. These findings support the current national policy for low-dose primaquine in Ethiopia without prior G6PD testing, if systems for monitoring adverse events are in place.

Overview

CoChat Summary

TL;DR

In a prospective observational study in Ethiopia, 879 patients with *P. vivax* or mixed malaria received chloroquine plus low-dose primaquine (0.25 mg/kg/day for 14 days) without prior G6PD testing; no G6PD-deficient patients were identified and no serious adverse events occurred. Low-dose primaquine was well tolerated with modest, mostly transient haemoglobin declines and 91.9% haematological recovery by day 13.

Key findings

  • Among 879 analysed patients, none had G6PD deficiency; among 298 female patients tested with the SD Biosensor, 3 (1.0%) had intermediate deficiency.
  • On day 3, the abstract reports a median fractional haemoglobin fall of −0.9% (range −51.9–61.3); 9 patients had a >25% haemoglobin drop, of whom 2 fell below 8 g/dL, all asymptomatic and completing the 14-day primaquine course. The results table reports mean haemoglobin decreased from 12.9 to 12.6 g/dL (mean absolute −0.3 g/dL; mean fractional −2.2%, SD 9.3).
  • On day 7, the median fractional drop was 0.8% (range −51.9–48.3%); 5 patients had a >25% haemoglobin decline between days 3 and 7. By day 13, 91.9% (808/879) had haematological recovery.
  • No serious adverse events were reported; 31 (3.5%) patients reported adverse events, all resolved without sequelae, and no participant recorded a urine colour score ≥5 (highest recorded score was 4).

Methods

  • Prospective observational study conducted May 2019–30 June 2021 at four purposively selected health centres in Oromia, Amhara, and SNNP regions; enrolled patients with uncomplicated *P. vivax* or mixed malaria, age ≥6 months, excluding severe malaria, haemoglobin <8 g/dL, pregnancy/breastfeeding a child ≤6 months, prior haemolysis, and other criteria.
  • Treatment was chloroquine (10 mg base/kg on days 0 and 1, 5 mg base/kg on day 2) plus primaquine 0.25 mg/kg/day for 14 days without prior G6PD testing; follow-up was on days 3, 7, 13, and 27, with haemoglobin by HemoCue, urine colour by Hillmen chart, G6PD by CareStart RDT or SD Biosensor on day 13/27, and adherence assessed by pill count.
  • Data were double-entered into Epi Info version 3.5 and analysed in Stata version 14; analyses described demographic characteristics and absolute/percent haemoglobin changes between days 0–3, 3–7, and 0–13, minimum haemoglobin, >25% proportional decrease, and haemoglobin <8 g/dL.

Limitations

  • Stated: no G6PD-deficient patients were enrolled, so the safety of low-dose primaquine in G6PD deficiency could not be assessed; there was no control group not administered primaquine, so haemoglobin changes cannot be attributed solely to primaquine; unmeasured confounders (nutritional deficiencies, haemoglobinopathies, baseline hydration, parasite density, recent/concurrent infections) were not assessed; recall and social desirability biases may affect adverse event and adherence reporting.
  • Evident from the text: G6PD testing was performed on day 13 or 27, after primaquine exposure, not at baseline; the qualitative CareStart test detects <30% activity and may miss intermediate deficiency; the study used the low-dose 0.25 mg/kg regimen, so findings do not directly address higher WHO 2025 recommended doses; purposive site selection and exclusion of patients with haemoglobin <8 g/dL limit generalizability.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s12936-025-05709-8

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Study profile
Fig. 1 Study profileCC BY-NC-ND · PubMed Central
Fig. 2 Histogram of glucose-6-phosphate dehydrogenase (G6PD) activity by the SD Biosensor test, by sex. The red, interrupted lines indicate the manufacturer-defined cutoffs: ≤ 4.0 U/g Hb for deficient status; 4.1-6.0 U/g Hb for intermediate status in females only; and ≥ 4.1 U/g Hb for normal status in males, and ≥ 6.1 U/g Hb for normal status in females
Fig. 2 Histogram of glucose-6-phosphate dehydrogenase (G6PD) activity by the SD Biosensor test, by sex. The red, interrupted lines indicate the manufacturer-defined cutoffs: ≤ 4.0 U/g Hb for deficient status; 4.1-6.0 U/g Hb for intermediate status in females only; and ≥ 4.1 U/g Hb for normal status in males, and ≥ 6.1 U/g Hb for normal status in femalesCC BY-NC-ND · PubMed Central
Fig. 3 Violin plot of haemoglobin concentration on days 0, 3, 7, and 13
Fig. 3 Violin plot of haemoglobin concentration on days 0, 3, 7, and 13CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 34 Not checked · 72 Own results and interpretations

49 more claims

Create a free account to see all 106 claims and to verify the 37 references still open.

See all claims — free account
  • Probably not a substantial claim. 34
  • It may state two separate claims as one. 33

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 5

Citations

Cites

Show all 26 references

Cited by

Still being checked.

Metadata

Authors
Shifraw, T., Abdelmenan, S., Zewde, A., Worku, A., Abera, A., Mohammed, H., Etana, K., Keating, J., Chibsa, S., Girma, S., Teka, H., Mumba, P., Murphy, M., Karmarkar, E., Price, R. N., Hwang, J., & Berhane, Y.
Affiliations
  • Addis Continental Institute of Public Health (ET)
  • Addis Ababa University (ET)
  • Federal Ministry of Health (ET)
  • Tulane University (US)
  • U.S. President's Malaria Initiative (US)
  • Centers for Disease Control and Prevention (US)
  • Mahidol University (TH)
Corresponding author
Shifraw, Tigest
Venue
Malaria Journal
Published
2025-12-08
Volume
25
Issue
1
Pages
27-27
ISSN
1475-2875 (ISSN-L)
OpenAlex
W4417102779
Cited by
0
References
26
FWCI
0.00
Type
journal article
Language
en
Open access
Licence
Locations
  • Malaria Journal (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
U.S. President's Malaria Initiative
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
  • Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Neonatal Health and Biochemistry
Keywords
primaquine, Plasmodium vivax, radical cure, glucose-6-phosphate dehydrogenase deficiency, hemolysis, haemoglobin decline, drug safety, adverse drug reactions, malaria treatment, Ethiopia, haematological recovery, mixed malaria infection, public health facilities
MeSH terms
Adolescent, Adult, Aged, Antimalarials, Child, Child, Preschool, Ethiopia, Female, Glucosephosphate Dehydrogenase Deficiency, Health Facilities, Humans, Male, Middle Aged, Plasmodium vivax, Primaquine, Prospective Studies, Malaria, Vivax, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Haematologic responses to primaquine used for radical cure of Plasmodium vivax in public health facilities in Ethiopia: a prospective observational study. https://app.cochat.ai/papers/10.1186/s12936-025-05709-8
The paper
Shifraw, T., Abdelmenan, S., Zewde, A., Worku, A., Abera, A., Mohammed, H., Etana, K., Keating, J., Chibsa, S., Girma, S., Teka, H., Mumba, P., Murphy, M., Karmarkar, E., Price, R. N., Hwang, J., & Berhane, Y. (2025). Haematologic responses to primaquine used for radical cure of Plasmodium vivax in public health facilities in Ethiopia: a prospective observational study. Malaria Journal. https://doi.org/10.1186/s12936-025-05709-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.